Cerebellum Identified as Promising Target for Easing Alcohol Withdrawal

Researchers at Washington State University have identified the cerebellum, a part of the brain long associated with movement and coordination, as a potential therapeutic target for addressing alcohol withdrawal. Their study, published in Neuropharmacology, points to new strategies that ease both the physical and emotional symptoms of withdrawal, which often drive relapse among people with alcohol use disorder (AUD).

Alcohol use disorder affects around 29 million Americans and is one of the leading preventable causes of death in the United States. Despite the availability of treatments, fewer than one in five individuals with AUD are able to maintain long-term sobriety. Withdrawal remains a critical barrier, with symptoms ranging from motor discoordination to significant emotional distress. 

Led by Nadia McLean, the team explored the cerebellum’s role in these processes. “By targeting the cerebellum, we were able to ease both the physical motor discoordination and the emotional distress of withdrawal—the symptoms that so often drive people back to drinking,” McLean explained.

Senior author David Rossi emphasized the emerging view of the cerebellum as more than just a motor control hub. “Half the neurons in the brain are in the cerebellum,” Rossi said. “It’s increasingly clear this region is involved in far more than just motor control—it plays a role in addiction, emotional regulation and even social engagement.”

Using mice as a model, the researchers showed that chronic alcohol exposure disrupts normal cerebellar signaling, essentially rewiring the brain to rely on alcohol. Removal of alcohol then triggers an overactive state that produces withdrawal symptoms. To counteract this, the researchers tested two strategies.

The first used a genetic approach, inserting receptors into cerebellar neurons that acted as an “off switch” to calm hyperactive brain activity and improve motor coordination during withdrawal. While effective in mice, this method would not be feasible for human therapy due to the need for genetic modification.

A second strategy showed greater potential for treatment. The team tested Compound 6, a synthetic drug developed in Austria that acts on a receptor found only in the cerebellum. In mice, it reduced withdrawal-induced anxiety without affecting other parts of the brain and carried low risk of abuse, as healthy mice avoided it.

“Compound 6 gave us a way to target the cerebellum without genetic modification,” McLean noted. “That makes it a much more realistic option for therapy, and it suggests this part of the brain could be a powerful target for treating alcohol withdrawal.”